{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:49:27Z","timestamp":1784065767458,"version":"3.55.0"},"reference-count":39,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Generalized anxiety disorder (GAD) in children and adolescents is associated with substantial morbidity and increases the risk of future psychopathology. However, relatively few psychopharmacologic studies have examined treatments for GAD in pediatric populations, especially in prepubertal youth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Children and adolescents aged 7\u201317 years of age with a primary diagnosis of GAD were treated with flexibly dosed escitalopram (10\u201320\u2009mg daily,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009138) or placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009137) for 8 weeks. Efficacy measures included the Pediatric Anxiety Rating Scale (PARS) for GAD, Clinical Global Impression of Severity (CGI-S) scale, Children's Global Assessment Scale (CGAS); safety measures included the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as adverse events (AEs), vital signs, and electrocardiographic and laboratory monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Escitalopram was superior to placebo in reducing anxiety symptoms of GAD, as seen in the difference in mean change from baseline to week 8 on the PARS severity for GAD score (least squares mean difference\u2009=\u2009\u22121.42;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.028). Functional improvement, as reflected by CGAS score, was numerically greater in escitalopram-treated patients compared with those receiving placebo (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.286), and discontinuation owing to AEs did not differ between the two groups. Vital signs, weight, laboratory, and electrocardiographic results were consistent with previous pediatric studies of escitalopram.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Escitalopram reduced anxiety symptoms and was well tolerated in pediatric patients with GAD. These findings confirm earlier reports of escitalopram efficacy in adolescents aged 12\u201317 years and extend the safety and tolerability data to children with GAD aged 7\u201311 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov Identifier:<\/jats:title>\n                    <jats:p>NCT03924323.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2023.0004","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T10:49:04Z","timestamp":1681901344000},"page":"91-100","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2641","authenticated-orcid":false,"given":"Jeffrey R.","family":"Strawn","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA."},{"name":"Anxiety Disorders Research Program, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA."},{"name":"Division of Child &amp; Adolescent Psychiatry and Division of Clinical Pharmacology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Moldauer","sequence":"additional","affiliation":[{"name":"Syneos Health, Morrisville, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah D.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Syneos Health, Morrisville, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Wise","sequence":"additional","affiliation":[{"name":"Syneos Health, Morrisville, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Bertzos","sequence":"additional","affiliation":[{"name":"Syneos Health, Morrisville, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Syneos Health, Morrisville, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Greenberg","sequence":"additional","affiliation":[{"name":"AbbVie, Lake Bluff, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie, Madison, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Gopalkrishnan","sequence":"additional","affiliation":[{"name":"AbbVie, Madison, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-6055","authenticated-orcid":false,"given":"Molly","family":"McVoy","sequence":"additional","affiliation":[{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA."},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Knutson","sequence":"additional","affiliation":[{"name":"Core Clinical Research, Everett, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00099"},{"key":"e_1_3_6_3_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Association: Washington DC; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12792"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.177"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291710001418"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.2007.01812.x"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2012.10.006"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0035458"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10578-013-0410-x"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17r12064"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.9.1017"},{"key":"e_1_3_6_13_1","unstructured":"Guy W (eds.). ECDEU Assessment Manual for Psychopharmacology. US Department of Heath Education and Welfare Public Health Service Alcohol Drug Abuse and Mental Health Administration: Rockville MD; 1976."},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.2"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201200058"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533558"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.2432"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-021-01186-0"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2020.11.023"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2019.10.013"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1943-278X.2012.00091.x"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104263441703"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2010.170"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200209000-00006"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.2.290"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.2008"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790100074010"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05305whi"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0198"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.13262"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2018.01.015"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13396"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111188"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0160"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.749692"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.01.008"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2021.09.265"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454602760386879"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804633"}],"updated-by":[{"DOI":"10.1089\/cap.2023.0004.correx","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000}}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2023.0004","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2023.0004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2023.0004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:36Z","timestamp":1777388196000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2023.0004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1089\/cap.2023.0004"],"URL":"https:\/\/doi.org\/10.1089\/cap.2023.0004","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}